ClinicalTrials.gg
Active, not recruitingNCT05998330LiverPALUpdated Nov 4, 2026

LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

An interventional study of LiverPAL in Liver Disease Chronic, End Stage Liver DIsease and Cirrhosis, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in End Stage Liver Disease with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. End Stage Liver Disease · United States.

Enrollment
12th of 48
220 · median 64
Started
2023
with 1 other
No phase
31 of 66
3 open now
Primary completion
2026-12
later than 3 of 14 live
Registered
61st of 66
by date
Lead sponsor
4 of 66
Massachusetts General Hospital

Among the 66 studies in End Stage Liver Disease with a site in United States, this one is the 12th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2023, is one of 31 with no phase, reaches primary completion later than 3 of the 14 other live ones, and was the 61st registered.

End Stage Liver Disease

155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.

Browse End Stage Liver Disease studies →

Open to participants now

9 of the 66 studies in End Stage Liver Disease with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in End Stage Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.

Read the detailed description

The main purpose of this study is to compare two types of care - usual hepatology care and usual hepatology care with early involvement of palliative care clinicians to see which is better for improving the experience of hospitalized patients with advanced liver disease (AdvLD).

The investigators aim to find out whether introducing hospitalized patients with AdvLD to the palliative care team that specializes in symptom management can improve the quality of life and physical and psychological symptoms that patients and families experience during their hospitalizations as well as enhance the quality of patients' end of life care.

03

Conditions studied

  • Liver Disease Chronic
  • End Stage Liver DIsease
  • Cirrhosis
  • Cirrhosis, Liver
  • Advanced Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria:

  1. Hospitalized patient with a diagnosis of advanced liver disease, defined as cirrhosis with one of the following (new or ongoing) within the prior six months from date of consent:

    • Ascites (requiring diuretics or serial large volume paracenteses)
    • Spontaneous bacterial peritonitis
    • Hepatic hydrothorax (requiring diuretics)
    • Variceal bleed (with one or more occurrences)
    • Overt hepatic encephalopathy (requiring medications)
  2. Ability to comprehend English

Patient Exclusion Criteria:

  1. Prior history of liver transplantation
  2. Have uncontrolled hepatic encephalopathy, cognitive impairment, psychiatric disorder or other comorbid condition which the primary medical, hepatology, and/or transplant surgery teams believes prohibits the ability to provide
  3. Current or recent (within 5 years of receiving curative cancer treatment) history of extrahepatic (excluding non-melanoma skin cancer)
  4. Presence of hepatocellular carcinoma beyond Milan criteria
  5. Are already receiving hospice care
  6. Receive a score of \<10 on the Simplified Animal Naming Test

Caregiver Inclusion Criteria

  1. Adult caregiver (≥ 18 years of age)
  2. A relative or friend identified by the patient upon whom the patient relies for help and who likely is to be present in-person during hospitalizations or clinic appointments, or willing to participate by phone
  3. Ability to comprehend English and can complete questionnaires

Caregiver Exclusion Criteria

1. Inability to comprehend English

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • No intervention
    Usual Hepatology Care

    Usual hepatology care

  • Experimental
    Usual Hepatology Care with Early Palliative Care

    Usual hepatology care with early palliative care

    Behavioral: LiverPAL

Interventions

  • BehavioralLiverPAL

    The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.

06

What researchers measure

Primary outcomes

  1. Patient Quality of Life (Functional Assessment of Chronic Illness Therapy - Palliative Care, FACIT-Pal) up t0 4 weeks

    Compare patient quality of life (FACIT-Pal) scores up to 4 weeks adjusting for baseline quality of life scores between the study arms. Score range 0-184 with higher scores indicating better quality of life.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Patient FACIT-Pal Score longitudinally between study arms

    Compare patient quality of life (FACIT-Pal) scores longitudinally between the study arms. Score range 0-184 with higher scores indicating better quality of life.

    Time frame: Up to 6 months

  2. Patient Symptom Burden (revised Edmonton Symptom Assessment Scale, ESAS-r)

    Compare patient symptom burden scores (ESAS-r) between the study arms. Score range 0-100 with higher scores indicating higher symptom burden.

    Time frame: Up to 6 months

  3. Patient Depression Symptoms (Hospital Anxiety and Depression Scale, HADS-D)

    Compare patient depression symptoms (HADS-D) between the study arms. Score range 0-21 with higher scores indicating higher depression symptoms.

    Time frame: Up to 6 months

  4. Patient Anxiety Symptoms (Hospital Anxiety and Depression Scale, HADS-A)

    Compare patient anxiety symptoms (HADS-A) between study arms. Score range 0-21 with higher scores indicating higher anxiety symptoms.

    Time frame: Up to 6 months

  5. Patient End-of-Life (EOL) Care Communication with Clinicians

    "Has \[participant\] talked with \[participant's\] doctor about the kind of medical care \[participant\] would want if \[participant\] were very sick or near the end of life?"

    Time frame: Final assessment prior to patient death or at 6 months

  6. Documentation of Patient End-of-Life (EOL) Care Preferences

    Compare documentation of EOL care preferences in the electronic health record between study arms since baseline.

    Time frame: After patient death, up to 60 months

07

Study locations

1 site
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 35 non-industry interventional studies with no phase under End Stage Liver Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 72. This study's planned 38 months is above that.

Counting every sponsor, half of 36 studies reached it within 28 months; a quarter within 21 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jul 2027 → Dec 2026 and completion Jul 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Aug 18, 2023
StartActual
Sep 20, 2023
Primary completionEst.
Dec 1, 2026was Jul 2027
CompletionEst.
May 1, 2027was Jul 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Primary completion
Jul 31, 2027→Dec 1, 2026
Nov 4, 2026
Study completion
Jul 31, 2027→May 1, 2027
Nov 4, 2026
Enrollment
200 (estimated)→220 (actual)
Nov 4, 2026
Secondary outcomes
18 removed
What changed in the outcomes
  • Removedother outcomePatient End-of-Life (EOL) CareTime frame: Within 30 days of patient death
  • Removedother outcomeCaregiver Quality of Life (PROMIS-29+2)Time frame: Up to 6 months
  • Removedother outcomeCaregiver Depression Symptoms (Hospital Anxiety and Depression Scale, HADS-D)Time frame: Up to 6 months
  • Removedother outcomeCaregiver Anxiety Symptoms (Hospital Anxiety and Depression Scale, HADS-A) between study arms.Time frame: Up to 6 months
  • Removedother outcomeCaregiver Burden (Zarit Burden Index 12, ZBI-12)Time frame: Up to 6 months
  • Removedother outcomeReceipt of goal-concordant end-of-life care - patient wishes followedTime frame: At least 1 month after patient death, up to 3 months
  • Removedother outcomeQuality of Life Near Death (QOD)Time frame: After patient death, up to 60 months
  • Removedother outcomeProlonged Grief Disorder (PG-13-R)Time frame: At least 12 months after patient death, up to 60 months
  • Removedother outcomeHealthcare Utilization at End-of-Life - HospiceTime frame: After patient death, up to 60 months
  • Removedother outcomeHealthcare Utilization at End-of-Life - Hospice length of stayTime frame: After patient death, up to 60 months
  • Removedother outcomeHealthcare Utilization - Days alive and out of the hospitalTime frame: Up to 6 months
  • Removedother outcomeHealthcare Utilization - liver transplantationTime frame: Up to 60 months
  • Removedother outcomePatient Coping (Brief COPE)Time frame: Up to 6 months
  • Removedother outcomeCaregiver Coping (Brief COPE)Time frame: Up to 6 months
  • Removedother outcomePatient Feeling Heard and Understood ScaleTime frame: Up to 6 months
  • Removedother outcomeCaregiver Feeling Heard and Understood ScaleTime frame: Up to 6 months
  • Removedother outcomePatient End-of-Life (EOL) Care Communication with CaregiversTime frame: Final assessment prior to patient death or at 6 months
  • Removedother outcomePatient Quality of Life (PROMIS-29+2)Time frame: Up to 6 months
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 31, 2027→Dec 1, 2026
    Study completion Jul 31, 2027→May 1, 2027
    Enrollment 200 (estimated)→220 (actual)
    Secondary outcomes 18 removed
    What changed in the outcomes
    • Removedother outcomePatient End-of-Life (EOL) CareTime frame: Within 30 days of patient death
    • Removedother outcomeCaregiver Quality of Life (PROMIS-29+2)Time frame: Up to 6 months
    • Removedother outcomeCaregiver Depression Symptoms (Hospital Anxiety and Depression Scale, HADS-D)Time frame: Up to 6 months
    • Removedother outcomeCaregiver Anxiety Symptoms (Hospital Anxiety and Depression Scale, HADS-A) between study arms.Time frame: Up to 6 months
    • Removedother outcomeCaregiver Burden (Zarit Burden Index 12, ZBI-12)Time frame: Up to 6 months
    • Removedother outcomeReceipt of goal-concordant end-of-life care - patient wishes followedTime frame: At least 1 month after patient death, up to 3 months
    • Removedother outcomeQuality of Life Near Death (QOD)Time frame: After patient death, up to 60 months
    • Removedother outcomeProlonged Grief Disorder (PG-13-R)Time frame: At least 12 months after patient death, up to 60 months
    • Removedother outcomeHealthcare Utilization at End-of-Life - HospiceTime frame: After patient death, up to 60 months
    • Removedother outcomeHealthcare Utilization at End-of-Life - Hospice length of stayTime frame: After patient death, up to 60 months
    • Removedother outcomeHealthcare Utilization - Days alive and out of the hospitalTime frame: Up to 6 months
    • Removedother outcomeHealthcare Utilization - liver transplantationTime frame: Up to 60 months
    • Removedother outcomePatient Coping (Brief COPE)Time frame: Up to 6 months
    • Removedother outcomeCaregiver Coping (Brief COPE)Time frame: Up to 6 months
    • Removedother outcomePatient Feeling Heard and Understood ScaleTime frame: Up to 6 months
    • Removedother outcomeCaregiver Feeling Heard and Understood ScaleTime frame: Up to 6 months
    • Removedother outcomePatient End-of-Life (EOL) Care Communication with CaregiversTime frame: Final assessment prior to patient death or at 6 months
    • Removedother outcomePatient Quality of Life (PROMIS-29+2)Time frame: Up to 6 months
    + 4 other changes: verification date, responsible party, contact details and site details
  2. Oct 7, 2026
    Minor edits only
    + 4 other changes: verification date, date precision, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05998330
Collaborators
Robert Wood Johnson Foundation, American Association for the Study of Liver Diseases, Cambia Health Foundation
Responsible party
Nneka nnaoke Ufere (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Aug 18, 2023
Start date
Sep 20, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Nneka Ufere, MD MSCE
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion